 | |
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral, intranasal, vaporization, intravenous, rectal, sublingual, subcutaneous |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII |
|
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C16H23NO |
| Molar mass | 245.366 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
α-Pyrrolidinohexiophenone (α-PHP, A-PHP, Aphp, alpha-PHP, α-Pyrrolidinohexanophenone, PV-7) is a synthetic stimulant drug of the cathinone class developed in the 1960s[2] which has been reported as a novel designer drug.[3][4][5][6][7]
α-Pyrrolidinohexiophenone is a longer chain homologue of α-PVP, having an extra carbon on the alkyl side chain. Regarding the potency of alpha-PHP in the brain, chemist Michael H. Baumann of the Designer Drug Research Unit (established by Baumann[8]) of the National Institute on Drug Abuse stated: "alpha-PHP might be even more potent than alpha-PVP"; this statement is based on laboratory tests of chemical reactivity.[9]
Pyrovalerone is a structural isomer of alpha-PHP.[10]
The President of the Republic of Italy classified cathinone and all structurally derived analogues (including pyrovalerone analogues) as narcotics in January 2012.[11][12]
Sweden's public health agency suggested to classify α-PHP as narcotic on June 1, 2015.[13]
As of October 2015, α-PHP is a controlled substance in China.[14]
In December 2019, the UNODC announced scheduling recommendations placing Alpha-PHP into Schedule II.[15]
As of 29 October 2021, α-PHP has been banned in the Netherlands under the 1971 Vienna Convention on Psychotropic Substances.[16]
In the US, a-PHP is a Schedule I controlled substance as of 2022.[17]
